Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
about
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsState-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicinesP-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.Receptor induction and targeted drug delivery: a new antileukaemia strategy.The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancerRelapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments.Mass spectrometry in the pharmacokinetic studies of anticancer natural products.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride.Nanomedicinal products: a survey on specific toxicity and side effects.Population pharmacokinetics of liposomal daunorubicin in children.Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.HPMA copolymer-phospholipase C and dextrin-phospholipase A2 as model triggers for polymer enzyme liposome therapy (PELT).
P2860
Q28818166-B416A6F7-ED6B-4B9B-98CB-4EF97A29C799Q34045119-1B67DAA4-6C43-4737-918E-0F82E3B0A55DQ34142289-0E65951A-2B93-4AC6-B802-EB269E9F262AQ35164785-80EBFD65-C968-4150-9EC0-86EFC82B994FQ36194655-ABE66185-4E84-4DB0-A23D-67C747056D5DQ36612320-80A419F3-4825-493F-A625-9D56FA86E7F0Q36624187-B5E70CA3-6785-4540-A944-7C0A7CAA34FAQ38033592-8A11941E-7422-4846-B88F-D79EB66A9DD8Q38155455-FB963409-5C5C-4182-B698-35AD251293DFQ38247299-AD19F82E-C68E-4F8A-9024-2A9DA266E244Q38568180-641021B9-5AF8-42A5-8185-AD985007726CQ38676164-37C777CA-BDF9-4DEA-982F-8397E4BD622CQ38997239-3CAB5BB2-8CE3-4E32-A33D-397537653B02Q41545896-BF396F1D-A18D-4CA9-BEDB-0AE68B6B3449Q42760004-8F618AF1-DE1E-41E2-ACAA-393BCE8B989BQ43883716-D562C45D-2565-481B-8B9C-41B42CE74FCCQ50879676-67B0F34E-3B52-4FE1-95C0-25A1EBD9BBBA
P2860
Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacokinetics of liposomal ...... acute lymphoblastic leukaemia.
@ast
Pharmacokinetics of liposomal ...... acute lymphoblastic leukaemia.
@en
type
label
Pharmacokinetics of liposomal ...... acute lymphoblastic leukaemia.
@ast
Pharmacokinetics of liposomal ...... acute lymphoblastic leukaemia.
@en
prefLabel
Pharmacokinetics of liposomal ...... acute lymphoblastic leukaemia.
@ast
Pharmacokinetics of liposomal ...... acute lymphoblastic leukaemia.
@en
P2093
P356
P1476
Pharmacokinetics of liposomal ...... acute lymphoblastic leukaemia.
@en
P2093
Auvrignon A
Baruchel A
Bellenger P
Bertrand Y
Gandemer V
Leverger G
Méchinaud F
P2888
P356
10.1007/S002800000206
P577
2001-01-01T00:00:00Z
P6179
1002364683